Ascendis Pharma (ASND) Reports Q3 Loss of EUR1.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ascendis Pharma A/S Reports Third Quarter 2017 Financial Results
November 16, 2017 4:01 PM EST- Phase 3 Program for TransCon Growth Hormone Advances and TransCon PTH Enters the Clinic -
- Conference Call Today at 4:30 p.m. Eastern Time -
COPENHAGEN, Denmark, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced financial results for the quarter ended September 30, 2017.
We are making progress every day towards achieving our Vision 20/20 strategic plan to establish Ascendis as a... More
